Myriad’s BRACAnalysis CDx is an in-vitro diagnostic device that detects mutations in BRCA1 and BRCA2 genes. Credit: Myriad Genetics.

Myriad Genetics has expanded its partnership to allow AstraZeneca and Merck to use its BRACAnalysis CDx companion diagnostic.

This in-vitro diagnostic device is designed to qualitatively detect and classify variants in protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The diagnostic analyses genomic DNA obtained from blood samples.

Under the alliance, AstraZeneca and Merck will use the companion diagnostic to detect germline BRCA mutations in metastatic castrate-resistant prostate (mCRPC) cancer patients that are participating in the Phase III PROfound clinical trial.

“There is a significant unmet medical need in men with metastatic castration-resistant prostate cancer and BRCA1/2 mutations.”

PROfound will compare the safety and efficacy of AstraZeneca’s Lynparza (olaparib) to enzalutamide or abiraterone acetate in patients with homologous recombination repair gene mutations that had an inadequate response to previous therapy using a new hormonal agent.

Based on the results, Myriad intends to seek US Food and Drug Administration (FDA) approval for BRACAnalysis CDx as a companion diagnostic to Lynparza.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Myriad Oncology president Nicole Lambert said: “Our companion diagnostic collaboration with AstraZeneca and Merck has led to significant advancements in precision treatment for patients with ovarian breast cancer.

“However, there is a significant unmet medical need in men with metastatic castration-resistant prostate cancer and BRCA1/2 mutations, which is an area where the utility of PARP inhibitors is being explored. We look forward to this exciting opportunity to potentially expand the use of BRACAnalysis CDx in this setting.”

Myriad and AstraZeneca initially partnered on Lynparza in 2007. The collaboration led to approvals of BRACAnalysis CDx as a companion diagnostic in various breast cancer and ovarian cancer indications.

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now